Biotechnological Advancements in Vaccine Development for Emerging Infectious Diseases: A Focus on COVID-19

Ritambhara1, Susmita Shukla1\*

1Applied Plant Biotechnology Research Lab, Centre for Plant and Environment Biotechnology Amity Institute of Biotechnology, Amity University, Noida (U.P), India

Taramla Raman2

2Dpt. Of Genetics and Plant Breeding, College of Agriculture, Eroisemba, nCAU, Imphal, India

**ABSTRACT**

In contemporary society, there is a growing awareness of the factors and situations that contribute to the spread of different infections. One should contemplate the individuals who may be at risk and assess the probability of potential infection. The severity of the coronavirus is much higher in those aged 60 and above, as well as those with pre-existing disorders such as lung or cardiac diseases, diabetes, or immunocompromised states. The transmission of the virus mostly occurs through airborne particles when people are in close proximity to an infected person, who expels these particles by respiration, sneezing, speaking, or whistling. These particles may then enter another individual's body through their oral, nasal, or ocular pathways, as well as through contact with contaminated surfaces. Contemporary sophisticated procedures, including magnetic resonance imaging (MRI), electroencephalography (EEG), magnetoencephalography (MEG), positron emission tomography (PET), and computed tomography (CT) scan, enable non-invasive examination of afflicted individuals, facilitating the exploration of concealed cerebral structures and yielding remarkable approaches for illness detection. One of the most recent technological advancements is the development of "Nanoshells," which are tiny particles coated with a layer of gold. The manipulation of the thickness of individual layers inside a nanoshell enables the deliberate design of structures that can selectively interact with certain frequencies of light. Due to their diminutive dimensions, nanoshells may be effectively incorporated inside a model and selectively accumulate at cancerous lesion sites via a disease-specific phenomenon known as enhanced permeation and retention. The rapid identification and diagnosis of diseases at the bedside may be facilitated by recent advancements in research, innovation, and successful clinical applications, as well as the development of novel tools. The need for novel diagnostic instruments is evident within the clinical setting, since accurate findings play a crucial role in the delivery of healthcare services. The provided information offers a comprehensive explanation of a patient's medical condition and sheds light on subsequent medical treatment options. The process of diagnosis is a complex and collaborative endeavor that involves the use of clinical reasoning and the gathering of evidence in order to determine a patient's medical condition. According to the publication "Improving Diagnosis in Health Care," the occurrence of analytic errors, which include both incorrect and delayed analysis, continues to adversely impact many dissatisfied individuals. Taking these factors into consideration, it is quite probable that a majority of individuals will encounter at least one significant error at some point in their lifetime, sometimes resulting in devastating consequences. Analytical errors have the potential to negatively impact patients by impeding or delaying appropriate therapy, administering unnecessary or harmful treatment, or resulting in psychological and financial consequences. The panel argued that enhancing the analytical engagement is not only feasible, but also encompasses ethical, professional, and overall well-being considerations. The use of contemporary technology has the potential to contribute significantly to the preservation of the whole human population, both now and in the future.

Keywords: Covid, nanotechnology, diseases, detection, and cure.

I. INTRODUCTION

The act of planning for future events involves envisioning and implementing innovative frameworks that aim to enhance the detection, identification, and monitoring of infectious diseases. Additionally, it involves assessing the potential impact of these frameworks on our ability to effectively manage future threats. There is a perceived resemblance between illnesses affecting humans, animals, and plants. Early identification and intervention have a crucial role in mitigating the transmission of diseases and reducing the risk of complications, hence resulting in substantial cost savings. Prominent concerns encompass several key areas, namely: the accessibility, ownership, and confidentiality of medical care and personal data; the regulation of handheld diagnostic devices, encompassing public access, recommendations for healthcare professionals, waste disposal, and quality assurance protocols; the screening for diseases at transportation hubs such as ports and airports, as well as the classification and handling of associated data. The misappropriation of exogenous occurrences: a significant portion of the advancements that will form the foundation of future disease management systems is now being developed for objectives unrelated to the control of infectious diseases. The issue at hand pertains to determining the most effective approach to enhance accessibility while ensuring its responsible use. For example, it would be very advantageous to enhance access to data from sources now unrelated to disease, such as remote monitoring and mobile tracking data, in order to better understand the reasons behind managing infectious diseases. The present concern is on the dilemma of enhancing accessibility while simultaneously safeguarding individual and security concerns. In order to maximize the potential benefits of future disease management frameworks, several key areas need to be considered. These include promoting interoperability and open access of disease management systems, improving access to intellectual property, harnessing the growing business interests of mass electronic manufacturers, devising strategies to stimulate diagnostics for diseases that may not be of interest to industry, such as SARS and diseases prevalent in developing countries, and effectively integrating future disease management systems within broader models for infectious disease prevention. The general populace should assess the potential societal "costs" associated with future illness management frameworks, such as increased population monitoring and heightened utilization of personal data, in order to determine the benefits of their commitment to these systems. Nevertheless, ensuring public engagement with the implementation of many anticipated future disease management systems will be crucial for their effective delivery.

Over the course of only one century, there has been a significant and rapid expansion of knowledge in several disciplines, including microbiology and parasitology, immunology, genetics, public health, and medicine. In conjunction with economic advancements, these developments have yielded various favorable transformations in human well-being, including a reduction in infant mortality rates, increased life expectancy, the near eradication of some infectious diseases, and the effective treatment of others. Furthermore, in recent times, there have been notable advancements in various fields, including genomics, proteomics, high throughput screening, advanced mechanics, imaging, and geological data frameworks. These advancements have had a transformative impact on the discovery of medications and the monitoring, prevention, treatment, and management of new and emerging infectious diseases [1–3]. However, the task of providing the necessary equipment to those folks who are in dire need of them is not a straightforward endeavor. Despite the efforts made by administrative organizations, examination institutions, private associations, public-private organizations, and community-based groups to mitigate the burden of infectious diseases, some challenges persist. Many individuals are unable to access life-saving advancements, including simple but effective interventions. There are a significant number of infectious diseases that remain little researched and poorly understood. Additionally, the development of interventions to combat these diseases is limited by a lack of commercial appeal. In order to mitigate the impact of pervasive diseases and enhance global equity, it is imperative to foster heightened levels of global accountability and establish novel frameworks of collaboration among stakeholders. These efforts are essential for devising innovative solutions and effectively implementing them in regions with the most pressing needs. The examination encompasses more than the pursuit of technological marvels and captivating images. The concept is on fostering a "culture of development". Development is closely associated with stimulating the pursuit of new discoveries, the advancement of tools for health interventions, comprehending the specific social contexts in which interventions will be implemented, and actively engaging with communities to ensure optimal and sustainable implementation and adoption [4]. Advancement entails not only adopting alternative approaches, but rather accomplishing tasks in a manner that is more pragmatic, influential, secure, and equitable. In this section, we use a technique based on frameworks to facilitate progress. The initial focus of this study involves a systematic analysis of the procedural guidelines for fostering a climate of progress in low and middle-income countries. Subsequently, the investigation delves into strategies for promoting innovative collaborations and product development specifically targeting infectious diseases. Additionally, the study explores the social movements that are essential for the adoption and implementation of health interventions, as well as the methods for enhancing research and training capabilities in these nations. Wellbeing development models acknowledge the interconnectedness of education, research, development (R&D), manufacturing, domestic and export markets, intellectual property, and regulatory policies [5]. It is essential to establish effective linkages between these diverse components in order to facilitate the efficient and timely response of both public and local frameworks to the exigencies of the nation. Exploration has a central role within a developmental framework, including the inception of ideas, the exploration of novel methods to interpretation, the formulation of strategic plans, and the establishment of guidelines [6-7]. In countries with high-income economies, the promotion of well-being includes the involvement of professionals from many sectors and disciplines. Traditionally, the funding for preparation and fundamental research is provided by the public sector, mostly via universities and government research institutions. Translational research and product development, such as model innovations or limited-scale production, are conducted by pharmaceutical companies or, alternatively, other organizations, or, depending on the national framework, government institutions. However, in countries with low wages, the healthcare system is often rudimentary and fragmented.

The occurrence of diseases, the year in which they emerged, and the number of deaths resulting from them, measured in millions.

|  |  |  |  |
| --- | --- | --- | --- |
| **Disease** | **Year of outbreak** | **Cause** | **Death (in million)** |
| Antonine plague | 165- 180 AD | NA | 60-70 |
| Plague of Justinian | 541- 549 AD | Yersinia pestis (bacteria) | 30-50 |
| Japanese smallpox | 735 – 737 AD | Variola virus | 1 |
| Black Death | 1346-1353 | Yersinia pestis (bacteria) | 75-200 |
| Smallpox | 1520 | Variola virus | 5-8 |
| 17th century great plagues | 1600 | Yersinia pestis (bacteria) | 3 |
| 18th century great plagues | 1700 | Yersinia pestis (bacteria) | 0.6 |
| Cholera | 1817-1824 | [Vibrio cholerae](https://en.wikipedia.org/wiki/Vibrio_cholerae) (bacteria) | 1-2 |
| The third plague | 1855-1945 | Yersinia pestis (bacteria) | 15 |
| Yellow fever | Late 1800 | Arbovirus | 0.1-0.15 |
| Spanish flu | 1918-1920 | Influenza A virus | 25-50 |
| Russian flu | 1889-1890 | Influenza | 1 |
| Asian flu | 1957-1958 | Influenza virus H2N2 | 1-4 |
| Hong Kong flu | 1968-1969 | Influenza H3N2 | 1-4 |
| HIV/AIDS | 1981-present | HIV virus | 40.1 |
| SARS | 2002-2004 | SARS associated coronavirus | 0.00077 |
| Swine flu | 2009-2010 | Influenza H1N1 | 0.284 |
| Ebola | 2013-2016 | Ebola virus | 0.011 |
| MERS | 2012-present | MERS related coronavirus | 0.00088 |
| Covid-19 | 2019-present | SARS coronavirus 2 | 17.5-31.4 |

Considering the ongoing Covid-19 epidemic, there has been a proliferation of mechanical applications and initiatives aimed at mitigating the transmission of the virus, providing medical treatment to patients, alleviating the burden on healthcare workers, and advancing the development of novel and effective vaccines. In the current era where enhanced information is sought by various stakeholders, such as pandemic disease modelers, state authorities, global organizations, and individuals practicing isolation or adhering to social distancing measures, digital information and surveillance technologies have been extensively utilized to gather data and establish robust evidence in support of public health decision-making. Artificial computers are being used to facilitate the monitoring of infections and enforcement of preventive measures. Simultaneously, scientists are rapidly using gene editing, synthetic biology, and nanotechnologies to prepare and evaluate forthcoming vaccines, treatments, and diagnostic methods. Blockchain technology has the potential to be used in several domains, including the tracking of viral outbreaks, monitoring of security payments, and management of medical supply chains. In addition, the utilization of 3D printing technology and open-source innovations seems to be well-suited for assisting governments and medical institutions worldwide in addressing the growing demand for medical equipment, such as facemasks, ventilators, and respiratory devices, while also enhancing the availability of essential medical supplies. Concurrently, the advancements in telemedicine provide a pragmatic approach to mitigate the transmission of the virus and alleviate strain on hospital capacity. By serving as a possible conduit, telehealth enables individuals with mild symptoms to remain at home while directing more severe cases to hospitals. Presented here is a limited overview of the current innovations employed, highlighting their essential features and significance in combating the Covid pandemic. The focus is primarily on monitoring and controlling the rapid transmission of the disease, as well as ensuring that public health agencies maintain their capacity to address the continuously growing demands resulting from this global crisis. The study also examines the fundamental legal and regulatory challenges, as well as the key socio-ethical dilemmas, that arise from the intricate implementation of these breakthroughs in a public health crisis context, such as the present situation.

The mechanical skyline's output in relation to Covid-19 allows for preliminary observations on the state of creative involvement in combating this unprecedented epidemic. Firstly, in contrast to previous public health crises, the current situation seems to be shifting individuals from being passive subjects of surveillance and epidemiological analysis to active participants in the information age. This is facilitated by self-tracking, sharing of data, and the utilization of digital information channels. Moreover, while numerous of these technological advancements have not been utilized in the context of a health-related crisis before, their widespread implementation on a global level raises questions regarding the implications for civil liberties pertaining to the deployment of mass surveillance tools. Additionally, concerns arise regarding the potential for state authorities to maintain heightened levels of surveillance even after the conclusion of the pandemic. Considering the ongoing pandemic, certain information collection and location tracking technological applications have been introduced under emergency legislation, which include the temporary suspension of fundamental rights and expedited authorization of medical devices and vaccines. While the primary focus of this study is on creative applications that address pressing pandemic-related challenges, it is important to note that this research does not aim to endorse the concept of techno-solutionism. In the context of complex cultural challenges, it is important to recognize that creative applications, in and of themselves, are insufficient in addressing these issues. This is shown by the challenges posed by the ongoing epidemic. The findings of this present study suggest that although innovation cannot replace or substitute for other public policy measures, it does play an increasingly crucial role in emergency responses. The coronavirus, being the predominant pandemic of the current century, presents a significant opportunity for policymakers and regulators to consider the legal validity, ethical adequacy, and effectiveness of deploying emerging technologies within a constrained timeframe. The priority of establishing harmony is crucial in maintaining public confidence in evidence-based interventions for public health.




Figure 1 illustrates the mortality rate seen during several pandemics over the years.

The significance of microorganisms in relation to human well-being in modern society remains paramount, although notable progress in the fields of infectious illness prevention and comprehension. During the mid-1900s, influenza, pneumonia, and tuberculosis were the predominant causes of mortality in emerging nations, owing to their high contagiousness. At present, cardiovascular disease and stroke are the primary contributors to death in these nations, while the risk of mortality from infectious diseases in less developed countries is akin to the circumstances observed in these nations a century ago. The potential hazards associated with a wide range of microorganisms have undergone modifications during the course of human civilization, mirroring the shifts in human behavior and emphasizing the complex interplay between bacteria and their hosts. Numerous diseases and their corresponding etiological agents have been successfully eliminated, although there is a growing presence of newly identified microbes. These microorganisms encompass not just unidentified or unconnected creatures, but also bacteria capable of host switching, potentially affecting human health. The incorporation of recently discovered non-destructive organisms into the human microbiota has been made possible due to the increased understanding in this field [8]. The improved understanding of the relationship between microbes has also revealed an elevated susceptibility to neoplasia in the presence of certain diseases [9-10], along with the possibility of one microbe-induced infection increasing the likelihood of other infections in humans [11]. The presence of certain human alleles has been suggested to potentially contribute to heightened vulnerability or resilience towards specific microbes [12-14]. The appearance of several drug-resistant bacterial strains, formerly susceptible to antibiotics, has resulted in a scenario reminiscent of the pre-antibiotic period. Some scholars have used the term "post-antibiotic era" to describe this situation [15]. The scientific subject of clinical microbiology came into existence during the later half of the nineteenth century. The contributions of Pasteur were essential in questioning the concept of "spontaneous generation" and in creating disinfection systems and aseptic techniques [17]. The presence of communicable diseases has long been a topic of inquiry and uncertainty. Koch's study on the germ theory of infection provided confirmation that microbes were the fundamental etiological agents responsible for many diseases [16]. In accordance with his notable theoretical framework, which sought to provide a uniform methodology for validating causation in the context of infectious diseases, it is imperative to show a direct correlation between the pathogen and the manifestation of the disease. The presence of the organic entity should be restricted to particular instances of the sickness, rather than being observed in unrelated conditions or in individuals without any medical ailments. In order to study the microbe, it is necessary to maintain a pure culture of the microorganism outside of its host organism. Additionally, the microbe should have the capability to induce the disease again when introduced into animals that are sensitive to it. For more than a century, the study of microorganisms and the detection of infectious diseases have heavily relied on the fundamental concepts of pure culture and clonality. These concepts involve the utilization of specific media and the isolation of individual colonies on solid medium. The utilization of DNA sequencing [18-19] and nucleic acid amplification-based methodologies [20-21] during the 1970s and 80s greatly facilitated the taxonomic classification of organisms by analyzing their genetic composition. Additionally, these techniques allowed for the potential identification of new microorganisms within a varied population, eliminating the requirement for prior cultivation. The process of replacing an inherent augmentation with an enzymatic amplification technique has been referred to as the "PCR as-petri-dish representation" in the literature [23]. The advancements made in this field have led to the development of proposed legislation aimed at identifying microorganisms and establishing causality in cases of illness [22].

Therefore, one may argue that these elements operate as catalysts for the substantial exacerbation or disruption of a stable internal equilibrium. The comprehension of viral contaminations and the historical patterns of sickness transmission remains constrained. Nevertheless, there is a scarcity of published data regarding the possible implications for human health concerning comprehensively characterized disorders [24]. Unanswered inquiries revolve around the potential ramifications of viral infections, whether occurring independently or as part of a certain sequence, on immunological functionality and overall well-being. Furthermore, there is still a lack of certainty regarding the correlation between the total number of viral infections or specific pathogens and the heightened morbidity or vulnerability to particular chronic diseases in specific individuals. The resolution of these intricate inquiries has posed a significant challenge until recent times, primarily attributable to the constrained accessibility of diagnostic methodologies for verifying the existence of a certain viral pathogen. The majority of diagnostic techniques employed for the identification of viral illnesses are based on the examination of viral nucleic acids or antiviral antibodies. The utilization of nucleic acid technology for the detection of viral RNA or DNA is widely regarded as the most sensitive method, especially during the initial phases of viral infection. Several recent studies (25-27) offer an extensive analysis of various widely acknowledged nucleic acid amplification techniques, such as polymerase chain reaction (PCR), rolling circle amplification, loop-mediated isothermal amplification, and DNA sequencing. The quantification of host antibodies, typically in the form of IgG reactivity against viruses, serves as a supplementary approach employed in viral diagnosis or as substantiation of prior infection. The enzyme-linked immunosorbent assay (ELISA) is a commonly employed methodology for the implementation of immunoassays. Nevertheless, modern techniques like as western blotting and Luminex are being employed for this objective [28]. Although NAT and immunizers are commonly employed in modern practices, several limitations exist. These tests often need extensive time and advanced laboratory equipment for analysis. Additionally, they tend to concentrate on a limited spectrum of target diseases and may yield results with limited precision.

Currently, there exists an urgent requirement for the creation and utilization of computerized innovations that can be efficiently employed across various phases of the COVID-19 pandemic. The aforementioned developments encompass data-driven illness surveillance, screening protocols, crisis management tactics, diagnostic methodologies, and continuous monitoring endeavors. The discourse also encompasses strategies that could potentially mitigate the vulnerability of healthcare providers to the infection. In December 2019, medical establishments initiated the process of recording instances of an unidentified ailment among individuals who had previously been exposed to the Huanan fish market located in Wuhan, Hubei, China. The new strain of the coronavirus (SARS-CoV-2), commonly referred to as COVID-19, was expeditiously discovered by researchers from patients diagnosed with pneumonia [29]. The number of verified cases of Coronavirus has surpassed that of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), attracting considerable global attention and impacting several sectors. As of April 13th, 2020, the recorded count of COVID-19 instances had surpassed 1,800,000, accompanied by a cumulative fatality count of 117,000. The COVID-19 pandemic has been officially classified by the World Health Organization (WHO) as a global calamity of substantial concern. The effectiveness of computerized health systems in detecting and combating global pandemics has been demonstrated during the outbreaks of Ebola and Severe Acute Respiratory Syndrome (SARS) [30-32]. The notion of digital health (DH) encompasses the connectivity and engagement of individuals and populations in the management of their health and well-being. This is accomplished through the cooperation of open and supportive provider networks functioning within adaptable, integrated, interoperable, and digitally empowered care settings. Healthcare delivery is transformed by the strategic utilization of digital tools and services [33]. In contemporary times, there has been a notable surge in digital health (DH) endeavors as a reaction to the unparalleled worldwide strain of COVID-19 on healthcare systems. This research aims to examine various strategies that has the potential to mitigate the vulnerability of healthcare providers to the virus. The objective of the audit is to continuously improve the field of digital health (DH) by enhancing the efficacy of measures aimed at preventing infectious diseases. Advanced Health provides a unique chance to utilize real-time data in order to enhance the prevention and management of quickly growing epidemics. In recent times, there have been instances of outbreaks such as SARS, H1N1, and Ebola, which have sparked considerable deliberations over the application of digital health (DH) in managing public health catastrophes. The insights acquired from these experiences can be utilized to build novel and more efficacious strategies aimed at augmenting our approach to the COVID-19 pandemic. The utilization of digital health (DH) has promise in augmenting our readiness for forthcoming pandemics. It is crucial that we properly fasten and organize these instruments in a stacked structure in anticipation of our upcoming encounter with an overwhelming disease.

Biosensors are analytical instruments that possess the ability to detect a wide range of biomolecules. They are frequently employed in the identification of clinically relevant pathogens, such as bacteria and viruses, and have demonstrated significant and remarkable results. In light of the enduring and intrinsic risk associated with the potential emergence of another pandemic akin to the ongoing COVID-19 crisis, analysts are consistently involved in the anticipation and advancement of innovative technologies designed to investigate and address diseases resulting from various bacteria and viruses. The domain of nanotechnology has achieved notable progress in augmenting the conceptualization and execution of biosensors. The advancements described can primarily be ascribed to the progress made in the field of new materials and nanoparticles, which have significantly augmented the capacity of biosensors to detect bacterial presence. Prominent illustrations encompass the utilization of nanoparticles, graphene quantum dots, and electro spun nanofibers, which have demonstrated augmented affinity, selectivity, and efficacy in the detection of microorganisms. The primary objective of this work is to conduct a thorough examination of the operational mechanisms of biosensors in the context of detecting bacterial and viral infections. Furthermore, this study delves into the progress made in the field of nanotechnology, specifically in relation to its role in facilitating prompt and efficient point-of-care detection of Covid-19. The biosensor concept was expeditiously explored by Clark and Lyons in approximately 1962, whereby they devised an oxidase compound cathode specifically for the detection of glucose [34]. Subsequent to that period, notable advancements have been made in the realm of nanotechnology, resulting in the emergence and refinement of biosensors tailored for diverse purposes [35]. At now, nanotechnology holds a prominent position in the realm of scientific progress. Its utilization in conjunction with bio-sensor applications spans across several fields like medicine, biology, environmental science, pharmaceutical delivery, and food processing [36-40]. Nevertheless, the identification of microorganisms has become a critical goal for these devices, as bacterial and viral diseases currently present a significant risk to human well-being [41-42]. The identification of diseases and microscopic organisms frequently necessitates the utilization of several molecular methodologies, including the reverse transcriptase polymerase chain reaction (RT-PCR), which is largely acknowledged as the most reliable method for microbial detection [43]. The usual techniques employed for the identification and detection of these bacteria often include separation, followed by subsequent refined and biochemical testing (44). Furthermore, serological techniques, such as the Enzyme-Linked Immunosorbent Assay (ELISA), are employed for the detection and discrimination of antibodies and immunoglobulins in order to facilitate their identification [45]. Nevertheless, it is important to acknowledge that a number of these strategies require a substantial time investment in order to yield outcomes, and are frequently characterized by their arduous nature. Recent advancements in nanotechnology have given rise to novel methodologies that offer promising and enhanced solutions for the prompt and efficient identification of microorganisms [44-46]. Nanoparticles (NPs) have demonstrated notable antibacterial properties, resulting in the emergence of novel products and advancements that contribute to the enhancement of public health [47-48].

Biosensors can be defined as a measurement device utilized for the identification of analytes, whereby a biological component is integrated with a physicochemical transducer [49]. The determination of the analyte is contingent upon the structure and justification of the biosensor. Soni et al. (year) have devised a non-invasive biosensor for the detection of urea, utilizing saliva as a sample medium. This biosensor may be easily integrated into widely utilized devices, such as smartphones, through the incorporation of uncomplicated accessories (Soni et al., year, p. 50-51). This facilitates expeditious and economical fundamental identification [52]. Biosensors frequently possess the capacity to discern biomolecules, including nucleic acids, proteins, and cells, that are correlated with disease states. The potentiality of this proposition may be contemplated in light of the existence of three essential constituents: the intrinsically sensitive element, the locating element, and the examining apparatus (53). Biomolecules, including proteins, microorganisms, organelles, antibodies, and nucleic acids, are employed in the context of biomolecule recognition [54]. Furthermore, it is important for analysts to discern the fundamental prerequisites necessary for acquiring a functional apparatus in accordance with its planned use. Therefore, it is imperative to incorporate interdisciplinary research in order to ascertain the appropriate material, transducing device, and natural component required prior to the assembly of the biosensor [55]. Biosensors are employed in clinical settings to discern biomolecules that are linked to certain disorders [53]. These devices possess the capacity to identify the biochemical markers of a disease in bodily fluids, including samples of saliva, blood, or urine [56-57].

**The coronavirus, commonly known as COVID-19, has been officially designated as a pandemic.**

COVID-19 is classified among the Corona viridine family, which falls under the Noroviruses order. This viral family is distinguished by the notable appearance of crown-like spikes on the surface of the virus. As a result, the viral infection was officially designated as Covid-19. Coronaviruses exhibit a relatively diminutive size, often measuring between 65 and 125 nanometers. Coronaviruses are characterized by possessing a nucleic material composed of single-stranded RNA, which typically ranges in length from 26 to 32 kilobases (kb) [58]. Multiple strains of Covid have the capacity to infect persons, including the widely distributed human coronaviruses HCoV-229E, HCoV-NL63, HCoV-HKU1, and HCoV-OC43, which typically induce moderate respiratory disease. Furthermore, it is worth noting the existence of zoonotic coronaviruses, including Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), which demonstrate a heightened fatality rate [59]. Originally named the 2019 novel coronavirus (2019-nCoV), the viral illness has subsequently been officially classified as SARS-CoV-2 by the International Committee on Taxonomy of Viruses (ICTV) [62]. The infection possesses the capacity to elicit a medical ailment often denoted as Covid infection 2019 (COVID-19) [62]. The SARS-CoV-2 virus is classified within the Betacoronavirus category, alongside the SARS and MERS viruses. These viruses have been associated with two notable epidemics that have had significant impacts in recent history. Similar to Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), it is postulated that the novel coronavirus, referred to as Covid-19 or 2019-nCoV, has its source in animals and can potentially be transferred through the respiratory tract, direct contact, and potentially through the excretions of infected persons, which may harbor viable viral particles [63].

The rapid spread of the 2019 novel coronavirus (2019-nCoV) outbreak, originating in Wuhan, China, has been observed in many regions of China as well as multiple other nations [64]. The global outbreak of COVID-19 has had a significant impact on a substantial number of individuals, affecting about 3 million people in 187 nations, regions, or territories. This widespread impact has resulted in a mortality rate of 4.2%. The aforementioned matter has arisen as a significant worldwide concern (Reference 65). Based on the available evidence indicating a notable surge in infection rates and the potential for transmission by asymptomatic individuals (references 66-67), it can be deduced that SARS-CoV-2 has the capacity to effectively disseminate within human populations and possesses a considerable propensity for instigating a pandemic (references 68-70). Until now, the illness has spread worldwide, presenting itself as a genuine and widespread ailment that significantly affects the overall status of human health [71]. Given the lack of targeted therapeutic medications or immunizations for the novel coronavirus disease (COVID-19) that emerged in 2019, it is imperative to promptly detect infections during their initial phases and expeditiously segregate infected individuals from the uninfected population. The objective of this study is to do a thorough analysis and documentation of the current body of knowledge regarding Covid Disease 2019 (COVID-19), including its causes, patterns of occurrence, clinical features, and approaches to therapy. There will be a particular focus on measures for controlling and preventing infections.

**The transmission of COVID-19 is a significant concern in the field of public health.**

In December 2019, the city of Wuhan in the Chinese province had a significant outbreak of a newly identified infectious disease known as COVID-19, the origins of which were first unclear [68-72]. Ongoing efforts are underway to gain more insights into the transmissibility, severity, and other characteristics associated with the Coronavirus [73]. In due course, an additional source of infection was identified as the transfer of the COVID-19 virus from one person to another [74]. Subsequent studies have indicated that individuals aged 60 years and older, as well as those with compromised immune function such as diabetes, cardiovascular disease, chronic respiratory disease, cancer, renal dysfunction, and hepatic dysfunction, are at a heightened risk for severe COVID-19. In contrast, younger individuals may be less susceptible to infection or, if infected, may exhibit milder symptoms or even remain asymptomatic carriers [75]. The global tally of confirmed cases exhibits notable increases in Korea, Iran, Italy, Spain, France, and Germany. The illness is also continuing to spread to African countries such as Algeria, South Africa, Senegal, Burkina Faso, Cameroon, Nigeria, and Côte d'Ivoire. Despite the confirmed evidence, the Ministry of Health in Morocco reports that the country has recorded over 4500 confirmed cases of the Covid-19 virus. The onset and dissemination of the COVID-19 virus. SARS-CoV-2 has been identified as a positive-stranded RNA virus belonging to the Betacoronavirus family, characterized by the presence of spike glycoproteins on its envelope [64]. In addition to SARS-CoV-2, individuals with Covid have been identified to be infected with six other types of coronaviruses, namely HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1, and MERS-CoV [76]. Scientists are now engaged in efforts to identify the animal reservoir of the new Covid in order to mitigate its transmission. However, as of yet, there is uncertainty surrounding this matter. The prevailing consensus among sources is that bats, pangolins, or fish are potential hosts of the 2019-nCoV [60-61,77]. The task at hand involves identifying and locating the individual responsible for transmitting the Covid virus to the population. Determining the source of the illness is crucial in facilitating the identification of zoonotic transmission patterns [77]. SARS-CoV-2 has a significant level of contagiousness and pathogenicity [79]. The transmission of the virus might potentially occur via human-to-human contact through droplets and direct physical touch [79]. Several studies have shown that persons displaying symptoms of COVID-19 are the primary drivers of its gearbox. The primary mode of transmission is by respiratory droplets expelled by an infected person, often through coughing or sneezing [78]. Moreover, there exists a notion that those who remain asymptomatic have the potential to transmit the virus. Moreover, it is anticipated that researchers will elucidate and grasp the mechanisms of transmission, the incubation period, and the duration of infectivity associated with this disease.





Figure 2 illustrates the obligatory health practices during the COVID-19 pandemic that must be adhered to in order to effectively combat the spread of the coronavirus.

The primary objective of this discussion is to provide a comprehensive analysis of the clinical features associated with COVID-19, a respiratory ailment induced by the recently discovered SARS-CoV-2 virus. Through a comprehensive review of existing scholarly literature and empirical data, the present analysis endeavors to investigate. In patients suffering from Coronavirus infection 2019 (COVID-19), the most commonly observed clinical presentations typically consist of fever, respiratory distress, and various respiratory problems, in addition to other non-specific symptoms such headache, dyspnea, fatigue, and myalgia [80-81]. Moreover, it has been observed that a specific group of individuals may experience gastrointestinal manifestations, including diarrhea and vomiting, as indicated by previous studies [79-81]. Previous studies have demonstrated that the clinical symptoms of the coronavirus bear resemblances to those observed in SARS and MERS (80). Based on the findings of the research, it was seen that a proportion of 18.7% of individuals who were confirmed to have COVID-19 did not display fever symptoms. This indicates that the absence of fever cannot always be considered as definitive evidence for ruling out the presence of COVID-19 [80]. In all cases, the manifestation of fever, with or without respiratory symptoms, is followed by the occurrence of lung abnormalities of varied severity, which can be observed through the use of CT scans [68,82]. Approximately 20-25% of individuals affected by MERS-CoV or SARS-CoV exhibit diarrhea, but there have been limited accounts of gastrointestinal symptoms in COVID-19 patients [83]. Chest CT filters are made available to patients in order to obtain accurate and dependable data regarding the unique X-ray pattern. Mild instances of pneumonia caused by COVID-19 frequently present as minor, subpleural, unilateral or bilateral opacities with an off-white appearance in the lower lobes of the lungs. The aforementioned opacities subsequently transition into a consolidative pattern, leading to future consolidation. After a duration of approximately two weeks, those who have successfully recuperated from COVID-19 pneumonia demonstrate a progressive merging of the abnormalities with remaining pearly glass opacities and subpleural parenchymal clusters [84]. Throughout the confirmation process, a significant proportion of patients demonstrated lymphopenia and platelet irregularities, including deviations in neutrophil levels, as well as aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and inflammatory markers. Based on the findings of post-procedural outcomes from computed tomography (CT) or X-ray exams, it was observed that a subgroup of patients exhibited both pneumonia and pleural effusion, with an incidence rate of 10.3%. When comparing recalcitrant individuals to the general patient population, it was shown that the former group exhibited elevated levels of neutrophils, AST, and LDH.

**The application of nanotechnology in the domain of disease diagnostics**

Nanotechnology is a scientific discipline that involves the study and control of particles and atoms within the size range of 0.1–100 nm. In contemporary discourse, this subject holds considerable sway over the advancement and trajectory of innovation, and has been extensively recorded as a vital phenomenon with worldwide implications in the 21st century. The notion of nanotechnology was initially proposed by Richard Feynman, an American physicist, in the year 1959. In 1989, the International Business Machines Corporation (IBM) employed xenon particles in the process of creating the recognizable brand name "IBM" via scanning tunnelling microscopy. Moreover, a direct demonstration of the generation of a single particle at the nuclear scale was observed. The formal establishment of nanotechnology as a field of study may be traced back to the notable International Conference on Nanotechnology, held in Baltimore in 1990. When examining the natural environment, it becomes evident that nanoparticles exhibit a wide range of captivating physical and chemical characteristics. These include effects related to their size, surface and interface properties, as well as their small size and the notable phenomenon of visible quantum tunnelling effects. Currently, a wide range of unique characteristics and exceptional phenomena of nanomaterials are observed, including the augmented surface area, enhanced surface reactivity, accelerated surface reaction kinetics, improved adsorption capacity, and higher catalytic capacity [85-87]. Moreover, a diverse array of attributes can be seen, including a decreased melting point, increased specific heat capacity, elevated coefficient of thermal expansion, accelerated reaction rate, enhanced diffusivity, heightened stability, and intensified magnetic attraction (88, 89). The field of nanotechnology has emerged as a viable option for advancing biomedical research. The integration of nanotechnology with medicine is commonly denoted as nanomedicine, wherein nanotechnology is employed to acquire crucial biological data at the molecular scale. The field of nano-biomedicine involves the processes of identifying, detecting, and treating diseases by proactive approaches. The utilization of ligand-conjugated nanostructures presents a potential avenue for the construction of intracellular or intercellular structures. The subsequent discussion pertains to the genuine behavior and pathophysiology of cells within this particular framework, with the aim of presenting substantial information that supports the timely identification and management of diverse medical conditions [90]. Presently, the field of nanomedicine mostly concentrates on the subsequent applications:

The integration of certain characteristics with nanomaterials has resulted in the emergence of nanomedical materials that demonstrate remarkable biocompatibility. The aforementioned materials have been purposefully developed for application in the fields of tissue engineering and regenerative medicine [91]. Quantum dots (QDs) demonstrate notable fluorescence properties in semiconductor nanomaterials, presenting a wide spectrum of excitation frequencies and a restricted range of emission frequencies, as opposed to traditional natural color particles. Hence, the outflow rate is limited and balanced, the cover size is minimal, the fluorescence yield is increased, and the level of security is considered acceptable. The utilization of a fluorescent test with an extended fluorescence lifespan has been recognized as an ideal approach for accurate disease diagnosis and ongoing disease monitoring [92]. The utilization of nanomaterials holds promise for the advancement of imaging and study techniques, hence augmenting the current capacities for observing nervous tissue. Furthermore, this methodology possesses the capability to establish a novel form of uninterrupted atomic imaging technology [93]. In light of the domain of nanotechnology, there exists the potential to design a versatile drug delivery system that places emphasis on its storage capabilities. This technology has the potential to boost drug delivery and improve targeted control, hence increasing the efficacy of drugs and broadening the scope of current pharmacological treatments. The mitigation of cytotoxicity effects induced by conventional pharmacological molecules can also be efficiently accomplished (source: [90]). The amalgamation of nanotechnology and clinical innovation has the promise of substantially broadening the range of medical interventions, augmenting the efficacy of therapy, and expediting advancements in the field of medicine.



The model depicted in Figure 3 is a little robotic device commonly known as a nanobot, which holds promise for application in the fields of healthcare and pharmaceuticals in the near future.

The ongoing identification of particular infections will have a substantial influence on our capacity to evaluate and deliver timely intervention for a wide array of diseases. Despite being historically regarded as improbable, new investigations have suggested the potential for identifying individual virus particles with a high degree of selectivity. The aforementioned objective is accomplished through the utilization of nanowire field-effect semiconductors, which enable the measurement of discrete alterations in conductance. These changes in conductance are indicative of the binding and unbinding occurrences taking place on nanowire clusters that have been functionalized with viral antibodies [93]. The exhibits have provided an analysis and differentiation of influenza, infections, paramyxoviruses, and adenoviruses based on their individual receptor binding characteristics and the duration of binding exhibited by each virus to its specific receptor. If the successful implementation of this technology on a clinical scale is achieved, it becomes highly feasible to utilize nanowire devices for the simultaneous detection of multiple unique diseases at the level of individual particles [91].

Without a doubt, the present-day society is confronted with a wide range of incapacitating conditions, including but not limited to diabetes, cancer, Parkinson's disease, Alzheimer's disease, cardiovascular problems, multiple sclerosis, as well as different serious inflammatory or infectious diseases such as HIV. The aforementioned ailments, distinguished by their severity and intricacy, endure as noteworthy obstacles for the global populace. Nano-medication is a term that pertains to the application of nanotechnology within the domains of healthcare and pharmaceuticals. Nano-medication encompasses the utilization of nanomaterials and nano-electronic biosensors. It is anticipated that atomic nanotechnology would yield substantial advantages in the realm of nano medicine in the forthcoming years [94]. The application of nanoscience within the healthcare sector presents numerous predicted advantages and holds substantial promise for the global population as a whole. Nanomedicine has been essential in facilitating the timely identification and mitigation of diseases, improving diagnostic accuracy, administering suitable treatments, and subsequently monitoring patient progress [95]. Nanoparticles are frequently employed as markers and identifiers in various applications. The incorporation of organic elements in these procedures enables expeditious implementation. Moreover, the progress made in testing procedures has led to heightened levels of sensitivity and adaptability. The advancement of nano devices, such as gold nanoparticles, has led to a substantial enhancement in the efficiency of quality sequencing. The utilization of nanoparticles in conjunction with short DNA segments has the potential to facilitate the identification of genetic sequences, hence exemplifying a notable application. The utilization of nanotechnology facilitates the reproduction or restoration of infected tissue. The cells that are allegedly activated in an erroneous manner are employed in the domain of tissue engineering, presenting the possibility of significantly transforming organ transplantation or the development of artificial implants [96].

Nano gadgets has the inherent capability to be employed in essential stem cell inquiries with the objective of monitoring and observing the behavior of these cells. Technology is utilized in both fundamental scientific research and translational medicine. The combination of nano transporters with organic particles enables the management of fundamental microorganisms. The use of nano devices holds promise in the fields of intracellular penetration, intelligent distribution, and biomolecule detection [96]. The aforementioned advancements exert a substantial influence on the microenvironment of stem cells and investigations in tissue engineering, and hold great potential for many biological applications. Nanoparticles are employed within the realm of nanotechnology to facilitate precise administration of pharmaceutical agents. This methodology entails administering the precise quantity of medication and thereafter observing a substantial decrease in results, as the active compound is entirely localized in the non-stimulatory area. The aforementioned highly specialized technique possesses the capacity to yield cost savings and mitigate patient suffering. Hence, a diverse array of nanoparticles, including dendrimers, as well as materials exhibiting nano-permeability, have been identified to possess numerous applications. Block co-polymer-derived micelles are employed for the encapsulation of medications. They enhance the delivery of minute medication particles to the most favorable place. Nano electromechanical systems (NEMS) find application in the medical domain for the delivery of pharmaceutical agents in a dynamic fashion. The utilization of iron nanoparticles with gold shells has gained significant traction in the realm of medical treatment, showcasing considerable promise in this area. Research has demonstrated that adopting a medicine-focused approach can effectively decrease drug utilization and treatment costs, hence improving the cost-effectiveness of healthcare for patients [96]. Nano medications utilized in pharmaceutical applications involve the utilization of nanoparticles or atoms at the nanoscale, exhibiting the capacity to augment the bioavailability of drugs. The utilization of nano-engineered devices, such as nano robots, is employed to achieve atomic targeting for the purpose of improving the bioavailability of drugs within specified regions of the body and for extended durations [98]. Selective targeting of particles [95] enables the precise localization of medication delivery to specific cells. The domain of in vivo imaging is currently witnessing advancements in the form of nano-scale equipment and systems that are tailored to cater to this specific objective. Nanoparticles serve as contrast agents in medical imaging modalities, including ultrasound and MRI, wherein they enable the visualization of nanoscale molecular pictures. Another medication delivery approach discussed in this context pertains to the use of nano shells or dielectric-metal nanospheres that are coated with silica and covered with a layer of gold. One possible advantageous application of nano shells is in their utilization for the targeted delivery of chemotherapeutic medicines to tumors. The development of nanostructured materials is currently underway to enhance the efficacy of treating many diseases and infections, including cancer (96). The progress in nanotechnology has facilitated the development of self-assembled nanodevices that are biocompatible and have the ability to identify cancer cells, independently assess the disease, administer therapy, and generate reports on the treatment outcomes [94]. The optimization of pharmacological and therapeutic attributes of medications can be attained through the proficient development of drug delivery systems, employing lipid and polymer-based nanoparticles [99]. The effectiveness of drug delivery systems is in their capacity to alter the pharmacokinetics and bio-distribution of the administered drug. Nanoparticles possess the capacity to circumvent the host's immune response and exhibit promise in augmenting the administration of therapeutic agents. Current research is focused on the development of novel pharmaceutical delivery methods that aim to boost the permeability of drugs across cellular membranes and enable their uptake into the cytoplasm, hence leading to improved overall efficiency. The utilization of medicinal compounds can be significantly improved through the process of catalysis. Pharmaceutical compounds that are introduced into the body have the ability to selectively react to specific stimuli. A pharmaceutical delivery method with improved solubility will be employed as a substitute for a medication that demonstrates restricted solubility (94). The utilization of nanoparticles has demonstrated benefits in enhancing the transportation of myelin antigens, hence inducing immune responses in a murine model displaying recurrent multiple sclerosis. This methodology entails the application of biodegradable polystyrene nanoparticles that have been coated with peptides obtained from the myelin sheath. Through the administration of these particles, the immune system of the mouse undergoes a reset, resulting in the prevention of disease recurrence and a decrease in symptom severity. The process of developing protective myelin sheath structures that envelop the nerve fibres of the central nervous system is responsible for this accomplishment. The therapy technique exhibits potential for application in the treatment of several immune system illnesses (100,101).

Nanoparticles possess a diminutive scale, rendering them exceedingly helpful within the realm of cancer research, particularly in the context of imaging applications. Nanoparticles, such as quantum dots, exhibit quantum control characteristics that enable the modulation of light emission based on their size. These particles have the potential to be utilized in combination with magnetic resonance imaging (MRI) to yield high-quality pictures of tumor locations. Nano particles demonstrate significantly greater brightness and require only a solitary light source for excitation, when contrasted with natural colors (94). Hence, the utilization of fluorescent quantum dots holds promise in yielding higher resolution images with improved contrast, while also offering a more economical alternative to conventional contrast agents in terms of cost. Nevertheless, it is important to acknowledge that quantum particles frequently consist of highly hazardous components. Nanoparticles offer a notable attribute of displaying a significant ratio of surface area to volume, facilitating the attachment of diverse functional groups to the nanoparticle, and subsequently forming bonds with specific tumor cells. Furthermore, the nanoparticles possess a diminutive size within the range of 10 to 100 nm, which facilitates their targeted accumulation specifically at tumor locations. This phenomenon can be attributed to the compromised lymphatic drainage system present in tumors. In the realm of future cancer therapy, there exists the potential to fabricate multifunctional nanoparticles that exhibit the capacity to detect, visualize, and subsequently target a tumor [102]. The Kanzius RF therapy entails the administration of nanoparticles at a very small scale to cells afflicted with disease. Subsequently, radio waves are employed to selectively raise the temperature of both the nanoparticles and the neighboring malignant cells. This process induces a localized thermal impact, akin to cooking, specifically targeting tumors within the body. Nanomaterials are characterized by their enhanced surface area and the manifestation of nano-scale phenomena, rendering them a very attractive resource for the progression of medical applications and gene delivery. These nanoparticles are utilized in diverse domains, including biomedical imaging, diagnostic biosensors, analytical procedures, detection approaches, and medicinal applications. Significantly, these nanoparticles are utilized in the specific targeting of cancer cells, facilitating drug administration, augmenting cellular and material interactions, advancing tissue engineering methodologies, and serving as gene delivery systems. These materials present novel prospects in the fight against severe illnesses (95). Significant advancements have been achieved in understanding the functionalities of organic structures and their interactions with diverse inanimate systems. Nevertheless, there are still unanswered inquiries, particularly about the suitability of materials and technologies that are implanted into the human body. Nanomaterials have remarkable physicochemical and organic properties when compared to their macroscopic counterparts. The interactions between nanomaterials and biological atoms and cells can be greatly influenced by several features of the nanomaterials. These characteristics include size, shape, chemical composition, surface architecture, charge, solubility, and aggregation [97]. For instance, the utilization of nanoparticles has demonstrated efficacy in generating high-quality visual representations of tumor sites. The utilization of single-walled carbon nanotubes has been observed as an effective method for transporting biomolecules into cellular structures. Nanomedicine holds promise for substantial breakthroughs across various fields, including medicine, communications, genetics, and robotics, among others (95). At a foundational level, the act of downsizing facilitates the advancement of mechanical, chemical, and biological components in terms of efficiency and speed. The behavior of items at the nanoscale scale is subject to forces that exhibit notable disparities from those exerted on larger-scale objects. The successful execution of these notable operations is what facilitates the viability of nanomedicine, and via further elucidation of these mechanisms, novel strategies for improving the well-being of individuals will be devised. Nevertheless, it is imperative to acknowledge that this particular procedure will require a substantial duration. It is anticipated that the incorporation of nanotechnology into clinical practice will become increasingly widespread in the near future. Considering that these gains will exhibit consistency and originate mostly from ongoing wet research as opposed to scaled-down machining and computing, it is possible that they may occasionally be of such minuscule magnitude that they are imperceptible. The amalgamation of nanotechnology with several other technological advancements holds significant potential for the future, facilitating the development of intricate and inventive hybrid technologies. Scientific progress is intricately connected to the realm of nanotechnology, which has been employed for the manipulation of genetic material and the fabrication of nano materials, encompassing biological constituents. The revolutionary impact of nanotechnology in manipulating matter at the nanoscale is evident in various disciplines, such as information technology, psychology, and biology. This has led to the establishment of unique interdisciplinary links between these sciences and others. Through extensive research and progress in the realm of nanotechnology, it is conceivable that this nascent sector holds potential advantages in various aspects of human existence. It is anticipated that advancements in nanotechnology would have a noteworthy influence on many crucial industries, such as medicine, regenerative medicine, stem cell research, and pharmaceuticals [94]. There is a considerable expectation that a wide range of nanoparticles and nanodevices will be employed, resulting in substantial advantages for human welfare. The primary goal is to improve the entire condition of well-being by enhancing the efficiency and security of nano systems and nanodevices. Furthermore, it is anticipated that there would be progress in the field of early detection techniques, the creation of inserts with improved characteristics, the management of malignancies, and the utilization of less intrusive pharmaceuticals for ailments such as coronary heart disease, diabetes, and other medical disorders [95]. Nanotechnology is anticipated to have a significant impact on the progression of medical practices in the foreseeable future. The proposed technology has novel prospects for the timely identification of illnesses, together with the implementation of diagnostic and therapeutic measures that aim to improve general health and optimize human physiological capacities. Furthermore, the field of nanotechnology holds the potential to enable the development of highly accurate and effective therapeutic approaches that may be customized to meet the specific needs of each patient.

**Conclusion**

With the continuous increase in the number of Covid cases seen over successive waves, it has become imperative to identify a lasting remedy for this ailment and similar infectious disorders. The average human lifespan is seeing a decline due to the prevalence of illnesses, despite advancements in medical sciences. The occurrence of a pandemic, which is mostly attributed to a particular illness, serves as a compelling reminder of the ongoing need for advancements in the medical domain. Presently, several nations are diligently engaged in the pursuit of identifying the genesis of this ailment, a pivotal stride towards averting the emergence of any future pandemic of similar magnitude. This chapter provides a comprehensive overview of the COVID-19 pandemic and several contemporary illnesses that pose threats to people, animals, and plants. It explores the strategies used in combating these diseases, including the processes of characterizing, identifying, modelling, developing vaccines, and using nanotechnology. These approaches together constitute significant components of the field of biotechnology. There are some emerging technologies that have not yet entered the market. However, it is essential to be prepared for their arrival, as the development of effective treatments is crucial. While COVID-19 poses a significant threat due to its mortality rate, it is comparatively lower than that of several other very lethal viruses and disorders. However, it is certain that another illness or pathogen may emerge in the future that might possess a higher fatality rate and more communicability, thereby posing an even greater danger to human existence than those we have experienced so far. The diligent preparation for a challenging examination beforehand proves to be worthwhile, as neglecting such preparation would need hasty abandonment of other commitments, analogous to the anticipation for the successful creation of a potent vaccine to safeguard our well-being. Nanotechnology is a potential solution to several challenges, as it enables the use of minuscule robotic particles that may assist in combating diseases and monitoring bodily processes. These particles have the capability to provide real-time information on changes inside the body, which can be conveniently accessed via mobile devices soon. The field of biotechnology encompasses a wide array of scientific applications that are used in several domains, including but not limited to healthcare and agriculture. The practice involves utilizing living organisms or their components to communicate innovative approaches for production and generate novel products, such as the development of new vaccines (via disease analysis) to prevent infection outbreaks, genetically modified plants (to cultivate resistance against various pests), and bacteria with the capability to remediate oil spills, among others. All these highlights are associated with biotechnology that is relevant to human healthcare. Overall, the field of biotechnology, particularly in relation to human healthcare, has a significant impact on the needs of patients and their families. This impact extends beyond the development of medications and also include the production of diagnostic tools using biotechnological methods. Furthermore, this encompasses the incorporation of quality and cell therapies, recombinant DNA products, tissue-engineered products, and the mitigation of environmental pollution. Currently, a significant proportion of innovative pharmaceuticals, whether produced using biotechnology or synthetic compounds, are readily available to the general population via the use of modern biotechnology in their development and scaling processes. Biotechnology plays a pivotal function in addressing diseases, encompassing many stages from diagnosis to the development and accessibility of vaccinations. The expeditious use of this technology is important in combating a wide range of detrimental illnesses.

##### REFERENCES

1. King DA et al. Epidemiology. Infectious diseases: preparing for the future. Science. 313(5792):1392–1393. 2006.
2. Diggle PJ et al. Spatial modelling and the prediction of Loa loa risk: decision making under uncertainty. Annals of Tropical Medicine and Parasitology. 101(6):499–509. 2007.
3. Thomson MC et al. Potential of environmental models to predict meningitis epidemics in Africa. Tropical Medicine and International Health. 11(6):781–788. 2006.
4. Mahoney RT, Morel CM. A global health innovations system (GHIS). Innovation Strategy Today. 2(1):1–12. 2006.
5. Morel C et al. Health innovation in developing countries to address diseases of the poor. Innovation Strategy Today. 1(1):1–15. 2005.
6. Matlin S, Samuels G. The global health research and innovation system (GHRIS). Lancet. 374(9702):1662–1663. 2009.
7. Gardner C, Acharya T, Yach D. Technological and social innovation: a unifying new paradigm for global health. Health Affairs. 26(4):1052–1061. 2007.
8. Labenz J and Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut 35:19-22. 1994.
9. Brechot C. Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma. Hepatology 25:772-774. 1997.
10. Zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 78:1-30. 1977.
11. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM and Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869. 1994.
12. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch FM, Gao XM, Takiguchi M, Greenwood BM, Townsend AR and et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360:434-439. 1992.
13. Apple RJ, Becker TM, Wheeler CM and Erlich HA. Comparison of human leukocyte antigen DRDQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J Natl Cancer Inst 87:427-436. 1995.
14. Michael NL. Host genetic influences on HIV-1 pathogenesis. Curr Opin Immunol 11:466-474. 1999.
15. Beardsley T. Paradise lost? Microbes mount a comeback as drug resistance spreads. Sci Am 267:18-20. 1992.
16. Koch R, in Clark, D. H. (Ed.), Source book of medical history, Dover Publications, Inc., New York. p.392-406. 1942.
17. Manchester KL. Louis Pasteur (1822-1895) chance and the prepared mind. Trends Biotechnol 13:511-515. 1995.
18. Maxam AM and Gilbert W. A new method for sequencing DNA. Proc Natl Acad Sci U S A 74:560-564. 1977.
19. Sanger F, Nicklen S and Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74:5463-5467. 1977.
20. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA and Arnheim N. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350-1354. 1985.
21. Mullis KB and Faloona FA. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155:335-350. 1987.
22. Fredericks DN and Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. Clin Microbiol Rev 9:18-33. 1996.
23. Persing DH, in D H Persing, T F Smith., F C Tenover and T J White (Ed.), Diagnostic Molecular Microbiology: Principles and Applications, ASM Press, Washington, D.C. p. 51-87. 1993.
24. Readhead B, Haure-Mirande JV, Funk CC et al. Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron. 99(1), 64–87. 2018.
25. Houldcroft CJ, Beale MA, Breuer J. Clinical and biological insights from viral genome sequencing. Nat. Rev. Microbiol. 15(3), 183–192. 2017.
26. Chang CC, Chen CC, Wei SC et al. Diagnostic devices for isothermal nucleic acid amplification. Sensors (Basel) 12(6), 8319–8337. 2012.
27. Gullett JC, Nolte FS. Quantitative nucleic acid amplification methods for viral infections. Clin. Chem. 61(1), 72–78. 2015.
28. Burbelo PD, Ching KH, Bush ER, Han BL, Iadarola MJ. Antibody-profiling technologies for studying humoral responses to infectious agents. Expert. Rev. Vaccines 9(6), 567–578. 2010.
29. Zhu, N.; Zhang, D.;Wang,W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi,W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733. 2020.
30. Bempong, N.E.; De Castañeda, R.R.; Schütte, S.; Bolon, I.; Keiser, O.; Escher, G.; Flahault. A. Precision Global Health—The case of Ebola: A scoping review. J. Glob. Health, 9. 2019.
31. Tom-Aba, D.; Nguku, P.; Arinze, C.; Krause, G. Assessing the Concepts and Designs of 58 Mobile Apps for the Management of the 2014-2015 West Africa Ebola Outbreak: Systematic Review. JMIR Public Health Surveill. 4, e68. 2018.
32. Eysenbach. G. SARS and Population Health Technology. J. Med. Internet Res., 5, e14. 2003.
33. HIMSS Defines Digital Health for the Global Healthcare Industry. Healthcare Information and Management Systems Society. 2020.
34. Clark, L.C.; Lyons, C. Electrode Systems for Continuous Monitoring in Cardiovascular Surgery. Ann. N. Y. Acad. Sci.102, 29–45. 1962.
35. Solaimuthu, A.; Vijayan, A.N.; Murali, P.; Korrapati, P.S. Nano-biosensors and their relevance in tissue engineering. Curr. Opin. Biomed. Eng. 13, 84–93. 2020.
36. Metkar, S.K.; Girigoswami, K. Diagnostic biosensors in medicine—A review. Biocatal. Agric. Biotechnol. 17, 271–283. 2019.
37. Lakshmipriya, T.; Gopinath, S.C.B. An Introduction to Biosensors and Biomolecules. In Nanobiosensors for Biomolecular Targeting; Gopinath, S.C.B., Lakshmipriya, T., Eds.; Elsevier: Amsterdam, The Netherlands, pp. 1–21. 2019.
38. Scholten, K.; Meng, E. A review of implantable biosensors for closed-loop glucose control and other drug delivery applications. Int. J. Pharm. 544, 319–334. 2018.
39. Yazdi, M.K.; Zarrintaj, P.; Bagheri, B.; Kim, Y.C.; Ganjali, M.R.; Saeb, M.R. Nanotechnology-based biosensors in drug delivery. In Nanoengineered Biomaterials for Advanced Drug Delivery; Mozafari, M., Ed.; Series in Biomaterials; Woodhead Publishing: Cambridge, MA, USA, pp. 767–779. 2020.
40. Griesche, C.; Baeumner, A.J. Biosensors to support sustainable agriculture and food safety. TrAC Trends Anal. Chem.128, 115906. 2020.
41. Pandey, A.; Gurbuz, Y.; Ozguz, V.; Niazi, J.H.; Qureshi, A. Graphene-interfaced electrical biosensor for label-free and sensitive detection of foodborne pathogenic E. coli O157:H7. Biosens. Bioelectron. 91, 225–231. 2017.
42. Cesewski, E.; Johnson, B.N. Electrochemical biosensors for pathogen detection. Biosens. Bioelectron.159, 112214. 2020.
43. Guliy, O.I.; Zaitsev, B.D.; Larionova, O.S.; Borodina, I.A. Virus Detection Methods and Biosensor Technologies. Biophysics 64, 890–897. 2019.
44. Farooq, U.; Yang, Q.; Ullah, M.W.; Wang, S. Bacterial biosensing: Recent advances in phage-based bioassays and biosensors. Biosens. Bioelectron. 118, 204–216. 2018.
45. Cheng, M.S.; Ho, J.S.; Tan, C.H.; Wong, J.P.S.; Ng, L.C.; Toh, C.-S. Development of an electrochemical membrane-based nanobiosensor for ultrasensitive detection of dengue virus. Anal. Chim. Acta 725, 74–80. 2012.
46. Sharma, A.; Sharma, N.; Kumari, A.; Lee, H.-J.; Kim, T.; Tripathi, K.M. Nano-carbon based sensors for bacterial detection and discrimination in clinical diagnosis: A junction between material science and biology. Appl. Mater. Today 18, 100467. 2020.
47. Rai, M.; Gade, A.; Gaikwad, S.; Marcato, P.D.; Durán, N. Biomedical applications of nanobiosensors: The state-of-the-art. J. Braz. Chem. Soc. 23, 14–24. 2012.
48. Zhao, V.X.T.; Wong, T.I.; Zheng, X.T.; Tan, Y.N.; Zhou, X. Colorimetric biosensors for point-of-care virus detections. Mater. Sci. Energy Technol. 3, 237–249. 2020.
49. Chao, J.; Zhu, D.; Zhang, Y.; Wang, L.; Fan, C. DNA nanotechnology-enabled biosensors. Biosens. Bioelectron. 76, 68–79. 2016.
50. Soni, A.; Surana, R.K.; Jha, S.K. Smartphone based optical biosensor for the detection of urea in saliva. Sens. Actuators B Chem. 269, 346–353. 2018.
51. Zhang, H.; Xue, L.; Huang, F.; Wang, S.; Wang, L.; Liu, N.; Lin, J. A capillary biosensor for rapid detection of Salmonella using Fe-nanocluster amplification and smart phone imaging. Biosens. Bioelectron. 127, 142–149. 2019.
52. Roda, A.; Michelini, E.; Zangheri, M.; Di Fusco, M.; Calabria, D.; Simoni, P. Smartphone-based biosensors: A critical review and perspectives. TrAC Trends Anal. Chem. 79, 317–325. 2016.
53. Choi, C. Integrated nanobiosensor technology for biomedical application. Nanobiosens. Dis. Diagn. 1, 1–4. 2012.
54. Srinivasan, B.; Tung, S. Development and Applications of Portable Biosensors. J. Lab. Autom. 20, 365–389. 2015.
55. Mehrotra, P. Biosensors and their applications—A review. J. Oral Biol. Craniofacial Res. 6, 153–159. 2016.
56. Krejcova, L.; Michalek, P.; Rodrigo, M.M.; Heger, Z.; Krizkova, S.; Vaculovicova, M.; Hynek, D.; Adam, V.; Kizek, R. Nanoscale virus biosensors: State of the art. Nanobiosens. Dis. Diagn. 4, 47–66. 2015.
57. Malon, R.S.P.; Sadir, S.; Balakrishnan, M.; Córcoles, E.P. Saliva-Based Biosensors: Noninvasive Monitoring Tool for Clinical Diagnostics. BioMed Res. 962903. 2014.
58. M. A. Shereen, S. Khan, A. Kazmi, N. Bashir, and R. Siddique. “COVID-19 infection: origin, transmission, and characteristics of human coronaviruses,” Journal of Advanced Research, vol. 24, pp. 91–98. 2020.
59. World Health Organization, Laboratory testing for coronavirus disease (COVID-19) in suspected human cases, World Health Organization. 2019.
60. H. Lu, C. W. Stratton, and Y. W. Tang. “Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle,” Journal of Medical Virology, vol. 92, no. 4, pp. 401- 402. 2020.
61. I. I. Bogoch, A. Watts, A. Thomas-Bachli, C. Huber, M. U. G. Kraemer, and K. Khan. “Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel,” Journal of Travel Medicine, vol. 27, no. 2. 2020.
62. A. E. Gorbalenya, S. C. Baker, R. S. Baric et al. “severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group,” BioRxiv. 2020.
63. H.-W. Zhang, J. Yu, H. J. Xu et al. “Corona virus international public health emergencies: implications for radiology management,” Academic Radiology, vol. 27, no. 4, pp. 463–467. 2020.
64. C. C. Lai, T.-P. Shih, W. C. Ko, H. J. Tang, and P.-R. Hsueh. “Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges,” International Journal of Antimicrobial Agents, vol. 55, no. 3, article 105924. 2020.
65. World Health Organization, “Coronavirus disease 2019 (COVID-19): Situation Report 61,”. 2020.
66. C. Biscayart, P. Angeleri, S. Lloveras, T. . S. S. Chaves, P. Schlagenhauf, and A. J. Rodríguez-Morales. “The next big threat to global health? 2019 novel coronavirus (2019-nCoV): what advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American society for travel medicine (SLAMVI),” Travel Medicine and Infectious Disease, vol. 33, article 101567. 2020.
67. S. Zhao, Q. Lin, J. Ran et al. “Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak,” International Journal of Infectious Diseases, vol. 92, pp. 214–217. 2020.
68. C. Huang, Y. Wang, X. Li et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The Lancet, vol. 395, no. 10223, pp. 497–506. 2020.
69. W. G. Carlos, C. S. Dela Cruz, B. Cao, S. Pasnick, and S. Jamil. “Novel Wuhan (2019-nCoV) coronavirus,” American Journal of Respiratory and Critical Care Medicine, vol. 201, no. 4, pp. P7–P8. 2020.
70. G. Chowell, F. Abdirizak, S. Lee et al. “Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study,” BMC Medicine, vol. 13, no. 1, p. 210. 2015.
71. C. Li, Y. Yang, and L. Ren. “Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species,” Infection, Genetics and Evolution, vol. 82, p. 104285. 2020.
72. F. Wu, S. Zhao, B. Yu et al. “A new coronavirus associated with human respiratory disease in China,” Nature, vol. 579, no. 7798, pp. 265–269. 2020.
73. S. P. Adhikari, S. Meng, Y. J. Wu et al. “Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review,” Infectious Diseases of Poverty, vol. 9, no. 1, p. 29. 2020.
74. H. Nishiura, S.-M. Jung, N. M. Linton et al. “The extent of transmission of novel coronavirus in Wuhan, China, 2020,” Journal of Clinical Medicine, vol. 9, no. 2, p. 330. 2020.
75. T. P. Velavan and C. G. Meyer. “The COVID-19 epidemic,” Tropical Medicine & International Health, vol. 25, no. 3, pp. 278–280. 2020.
76. F. A. Rabi, M. S. al Zoubi, G. A. Kasasbeh, D. M. Salameh, and A. D. al-Nasser. “SARS-CoV-2 and coronavirus disease 2019: what we know so far,” Pathogens, vol. 9, no. 3, p. 231. 2020.
77. Y.-H. Jin, L. Cai, Z.-S. Cheng et al. “A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version),” Military Medical Research, vol. 7, no. 1, p. 4. 2020.
78. H. A. Rothan and S. N. Byrareddy. “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak,” Journal of Autoimmunity, vol. 109, article 102433. 2020.
79. Y. Han and H. Yang. “The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): a Chinese perspective,” Journal of Medical Virology, vol. 92, no. 6, pp. 639–644. 2020.
80. P. Mo, Y. Xing, Y. Xiao et al. “Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China,” Clinical Infectious Diseases. 2020.
81. W. Wang, J. Tang, and F. Wei. “Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China,” Journal of Medical Virology, vol. 92, no. 4, pp. 441– 447. 2020.
82. D. Wang, B. Hu, C. Hu et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China,” JAMA, vol. 323, no. 11, pp. 1061–1069. 2020.
83. A. R. Sahin, A. Erdogan, P. M. Agaoglu et al. “2019 novel coronavirus (COVID-19) outbreak: a review of the current literature,” Eurasian Journal of Medicine and Oncology, vol. 4, no. 1, pp. 1–7. 2020.
84. F. Pan, T. Ye, P. Sun et al. “Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia,” Radiology, no. article 200370. 2020.
85. Fissell WH. What is nanotechnology? Adv. Chronic Kidney Dis. 20, 452–453. 2013.
86. Rasheed PA, Sandhyarani N. Carbon nanostructures as immobilization platform for DNA: a review on current progress in electrochemical DNA sensors. Biosens. Bioelectron. 97, 226–237. 2017.
87. Qiu H, Min YZ, Rodgers Z, Zhang LZ, Wang AZ. Nanomedicine approaches to improve cancer immunotherapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 9, e1456. 2017.
88. Manickam V, Velusamy RK, Lochana R, Amiti, Rajendran B, Tamizhselvi R. Applications and genotoxicity of nanomaterials in the food industry. Environ. Chem. Lett. 15, 399–412. 2017.
89. Damborska D, Bertok T, Dosekova E, Holazova A, Lorencova L, Kasak P, Tkac J. Nanomaterial-based biosensors for detection of prostate specific antigen. Microchim. Acta 184, 3049–3067. 2017.
90. Akhtar MJ, Ahamed M, Alhadlaq HA, Alrokayan SA, Kumar S. Targeted anticancer therapy: over-expressed receptors and nanotechnology. Clin. Chim. Acta 436, 78–92. 2014.
91. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12, 991–1003. 2013.
92. Peng L, He M, Chen B, Wu Q, Zhang Z, Pang D, Zhu Y, Hu B. Cellular uptake, elimination and toxicity of CdSe/ZnS quantum dots in HepG2 cells. Biomaterials 34, 9545–9558. 2013.
93. Su XY, Liu PD, Wu H, Gu N. Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy. Cancer Biol. Med. 11, 86–91. 2014.
94. Nanotechnology and its Applications in Medicine Anna Pratima Nikalje\* Department of Pharmaceutical chemistry, Y.B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Rauza Bagh, Aurangabad- 431001, Maharashtra, India.
95. Nanotechnology in Medicine: The Medicine of Tomorrow and Nanomedicine Logothetidis S Aristotle University of Thessaloniki, Physics Department Lab for Thin Films - Nanosystems & Nanometrology, GR-54124 Thessaloniki, Greece.
96. Nanomedicine – prospective therapeutic and diagnostic applications Dwaine F Emerich LCT BioPharma, 766 Laten Knight Rd,Cranston, RI 02921, USA.
97. Biomedical Applications of Nanotechnology by ineke malsch. Abraham SA Researchers Develop Bucky balls to Fight Allergy. Virginia Commonwealth University Communications and Public Relations. 2010.
98. lanza GM, Trousil RL, WALLACE KD et al.: In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. J. Acoust. Soc. Am. 104: 3665-3672. 1998.
99. Laurance J Scientists develop nanoparticle method to help tackle major diseases. The Independent. 2012.
100. Miller Stephen, Getts D, Martin A, McCarthy D, Terry R, et al. Micro particles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nature Biotechnology. 30: 1217-1224. 2012.
101. Nie S, Xing Y, Kim GJ, Simons JW Nanotechnology applications in cancer. Annu Rev Biomed Eng. 9: 257-288. 2007.
102. Zheng G, Patolsky F, Cui Y, Wang WU, Lieber CM Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnology. 23: 1294-1301. 2005.